Source: Rounding The Earth Author: Mathew Crawford

Since sometime last summer, I’ve paid (increasing) attention to much of the rapidly growing body of evidence that ivermectin (IVM) effectively treats SARS-CoV-2 and COVID-19. While I decided some months ago that I believe IVM almost surely works as a treatment and could effectively end the pandemic, the strange consistency of IVM results as prophylaxis, early (like antiviral), late, and as a long haul treatment baffled me. Could it really be true that IVM works in so many different ways that it manages all these results?!

While IVM has immuno-modulatory and anti-inflammatory properties, so too does hydroxychloroquine, but the evidence on HCQ efficacy quite clearly favors prophylaxis/early usage over late treatment, indicating that antiviral action is the most important tool in HCQ’s Swiss Army Knife array of mechanisms.

What could IVM be doing differently? Or is there just noise in the smaller body of research results (relative to HCQ’s) that masks a time-dependence for the use of IVM that will be revealed in further research? An answer may have presented itself…

Recently, at least two papers have come out (Chen et al; and Solomay et al) reporting that SARS-CoV-2 infections are associated with reactivation of the Epstein-Barr virus (EBV). A few days later, another paper (Gold et al) demonstrated the relationship between EBV and Long COVID. EBV is a herpes virus often called “the kissing disease” that affects 95% of the human population. In many people, it causes no immediate problems, but upon infecting a host it can cause fever, headaches, skin rashes, mononucleosis, and some autoimmune disorders. After infection, EBV remains latent in the host, but can be reactivated by an array of stimuli, some of which may be epigenetic stress responses. Perhaps this story is a nod to terrain theory.

blank

One particularly interesting aspect of the observation that SARS-CoV-2 seems to reactivate EBV is that ivermectin has been noted to have antiviral properties that treat EBV (not to mention numerous other viruses). This may be why ivermectin seems not only to work as a prophylaxis and in early treatment of COVID-19 patients, but also with late patients and even with long haul COVID-19 sufferers!

Even better, since EBV is linked to the development of several cancers, that means that ivermectin’s antiviral properties may provide a unique form of cancer protection!

And now your moment of zen, brought to you by Dr. Pierre Kory, evolutionary biologist Bret Weinstein, and podcast deity Joe Rogan:

Part A:

video

Part B:

video

Part C:

video









The Chloroquine Wars Part XX – Why The Early Treatment Data is Better Than Anyone Imagines

The Chloroquine Wars Part XXI

Dr. Peter McCullough’s Common Sense Breakdown of the Pandemic – The Chloroquine Wars Part XXIII

Doctor Didier Raoult Part I: Where We Are Now -The Chloroquine Wars Part XXV

Everything Bret Weinstein, Heather Heying, and Pierre Kory Missed About “The Crime of the Century” The Chloroquine Wars Part XXVI

Journal Editors Resign Over Suppression of Ivermectin Research Paper – The Chloroquine Wars Part XXVII

What if the SARS-CoV-2 Virus is Weaker Than Most Everyone Thinks? – The Chloroquine Wars Part XXVIII

Institutional Funding of Propaganda Against Early Treatment of COVID-19 – The Chloroquine Wars Part XXX

India Treats Medical Staff Prophylactically and Early, and It Makes a Difference – The Chloroquine Wars Part XXXI

How to Rig Research: The WHO Edition – The Chloroquine Wars Part XXXIII

How to Rig Research: The WHO Edition Part II – The Chloroquine Wars Part XXXIV

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

A Conversation With Dr. Brian Tyson – The Chloroquine Wars Part XLI

The data from the vaccine trials must be recalculated under the lens that some of the serious adverse events (SAEs) should be treated as COVID-19 cases.
There may not be any vaccine efficacy in the data at all if some of the post-vaccination deaths are due to vaccine-induced COVID-19. It could even be the case that the mortality efficacy goes negative. My implied lives saved calculations put this easily in the realm of possibility. The only way to know is for authorities to organize and compile the data. And while a risk analysis is certainly due after more than six months of hundreds of millions of doses delivered, there is little indication authorities have bothered with the process. That’s more than a bit unsettling.

Read More »

Dr. Brian Tyson, USA: Hydroxychloroquine – Data, Strategies and Success Treating over 6000 Covid Patients

We continue to delve extensively into the COVID-19 data with esteemed statistician, Mathew Crawford. In this episode, we take a closer look at the use of early treatment and its success. Mathew has been researching the data from Dr. Brian Tyson, who has successfully treated over 6000 patients who contracted COVID throughout the pandemic. It is my great honor to have Dr. Tyson here on this episode to not only discuss the data, but also the strategies that he has been using throughout the pandemic.

Read More »